NGNE NASDAQ
Neurogene Inc.
1W: -11.7%
1M: +1.2%
3M: +56.5%
YTD: +37.0%
1Y: +48.8%
3Y: +56.9%
5Y: -87.7%
$27.71
+0.10 (+0.36%)
Weekly Expected Move ±8.7%
$25
$27
$30
$32
$35
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$437.9M
52W Range14.65-37.266
Volume83,651
Avg Volume184,211
Beta2.08
Dividend—
Analyst Ratings
Company Info
CEORachel L. McMinn
Employees107
SectorHealthcare
IndustryBiotechnology
IPO Date2014-03-07
Websiteneurogene.com
535 W 24th Street
New York City, NY 10011
US
New York City, NY 10011
US
(877) 237-5020
About Neurogene Inc.
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Latest News
Neurogene (NASDAQ:NGNE) Shares Up 0.1% – Here’s What Happened
Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Price Target at $44.00
Equities Analysts Set Expectations for Neurogene Q1 Earnings
HC Wainwright Weighs in on Neurogene FY2027 Earnings
Q1 Earnings Estimate for Neurogene Issued By Lifesci Capital
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Cvijic Christine Mik | S-Sale | 4,800 | $30.07 | 2026-05-06 |
| Cvijic Christine Mik | S-Sale | 4,800 | $32.44 | 2026-05-06 |
| Shafer Christina | A-Award | 120,000 | $28.94 | 2026-05-05 |
| Shafer Christina | 0 | — | 2026-04-20 | |
| Cvijic Christine Mik | S-Sale | 2,558 | $21.62 | 2026-03-26 |